MetaVia (MTVA) Common Equity (2015 - 2026)
MetaVia's (MTVA) quarterly Common Equity came in at $5.3 million in Q4 2025, down 32.76% YoY from $7.9 million in Q4 2024, and down 15.76% on a QoQ basis from $6.3 million in Q3 2025.
MetaVia (MTVA) Common Equity (2015 - 2026) Analysis & Trends
MetaVia (MTVA) has 11 years of Common Equity data on file, last reported at $5.3 million in Q4 2025.
- Quarterly Common Equity fell 32.76% year-over-year to $5.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.3 million (down 32.76% YoY) and the FY2025 annual result came in at $5.3 million, down 32.76% from the prior year.
- Common Equity fell to $5.3 million in Q4 2025, from $6.3 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $25.2 million in Q2 2023 to a low of $4.4 million in Q1 2025.
- A 5-year average of $12.6 million and a median of $11.0 million in 2022 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2023 — Common Equity jumped 262.92% — and 2025, when it sank 56.53%.
- Tracing MTVA's Common Equity over 5 years: stood at $14.6 million in 2021, then surged by 49.0% to $21.8 million in 2022, then declined by 23.29% to $16.7 million in 2023, then tumbled by 52.47% to $7.9 million in 2024, then sank by 32.76% to $5.3 million in 2025.
- The last three Common Equity figures came in at $5.3 million (Q4 2025), $6.3 million (Q3 2025), and $9.6 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | MetaVia | 8.72 Mn | -3.92 Mn | - | 6.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.82 Mn |
| Dec 31, 2025 | 5.33 Mn |
| Sep 30, 2025 | 6.33 Mn |
| Jun 30, 2025 | 9.62 Mn |
| Mar 31, 2025 | 4.38 Mn |
| Dec 31, 2024 | 7.93 Mn |
| Sep 30, 2024 | 12.95 Mn |
| Jun 30, 2024 | 18.94 Mn |
| Mar 31, 2024 | 10.08 Mn |
| Dec 31, 2023 | 16.69 Mn |
| Sep 30, 2023 | 21.55 Mn |
| Jun 30, 2023 | 25.20 Mn |
| Mar 31, 2023 | 20.51 Mn |
| Dec 31, 2022 | 21.75 Mn |
| Sep 30, 2022 | 5.94 Mn |
| Jun 30, 2022 | 8.83 Mn |
| Mar 31, 2022 | 11.93 Mn |
| Dec 31, 2021 | 14.60 Mn |
| Sep 30, 2021 | 6.13 Mn |
| Jun 30, 2021 | 9.48 Mn |